UM

Browse/Search Results:  1-8 of 8 Help

Selected(0)Clear Items/Page:    Sort:
Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2018,Volume: 838,Page: 41-52
Authors:  Yang, Zheng;  Zhang, Shao-Lin;  Hu, Xiaohui;  Tam, Kin Yip
Favorite  |  View/Download:12/0  |  Submit date:2018/10/30
Dichloroacetophenone  Epidermal growth factor receptor  Tyrosine kinase inhibitor  Synergism  Hypoxia  Oxidative phosphorylation  
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes Journal article
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2018,Volume: 14,Issue: 2,Page: 204-216
Authors:  Yang, Zheng;  Tam, Kin Yip
Favorite  |  View/Download:12/0  |  Submit date:2018/10/30
Combination  Egfr-tki  Nsclc  Chemotherapy  Targeted Therapy  Immunotherapy  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
CANCER LETTERS, 2018,Volume: 420,Page: 242-246
Authors:  Tang, Zheng-Hai;  Lu, Jin-Jian
Favorite  |  View/Download:9/0  |  Submit date:2018/10/30
Osimertinib  Azd9291  Egfr Tki  Resistant Mechanisms  Therapeutic Strategies  
Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells Journal article
Anti-Cancer Agents in Medicinal Chemistry, 2018,Volume: 18,Issue: 4,Page: 550-555
Authors:  Tang Z.-H.;  Su M.-X.;  Guo X.;  Jiang X.-M.;  Jia L.;  Chen X.;  Lu J.-J.
Favorite  |  View/Download:3/0  |  Submit date:2018/12/28
Azd9291  Egfr  Ire1α  Lune Cancer  Nsclc  Osimertinib  
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells Journal article
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017,Volume: 815,Page: 80-87
Authors:  Yang, Zheng;  Hu, Xiaohui;  Zhang, Shaolin;  Zhang, Wen;  Tam, Kin Yip
Favorite  |  View/Download:19/0  |  Submit date:2018/10/30
Synergism  Dichloroacetophenone  Dichloroacetate  Egfr  Apoptosis  Acquired Resistance  
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells Journal article
ACTA PHARMACOLOGICA SINICA, 2017,Volume: 38,Issue: 11,Page: 1512-1520
Authors:  Jiang, Xiao-Ming;  Xu, Yu-Lian;  Huang, Mu-Yang;  Zhang, Le-Le;  Su, Min-Xia;  Chen, Xiuping;  Lu, Jin-Jian
Favorite  |  View/Download:15/0  |  Submit date:2018/10/30
Non-small Cell Lung Cancer  Egfr  Osimertinib  Pd-l1  Ubiquitin-proteasome System  Mg-132  Bortezomib  Gsk3 Beta  Licl  
Targeting the sheddase activity of Adam17 by an Anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation Journal article
International Journal of Biological Sciences, 2014,Volume: 10,Issue: 7,Page: 702-714
Authors:  Huang Y.;  Benaich N.;  Tape C.;  Kwok H.F.;  Murphy G.
Favorite  |  View/Download:4/0  |  Submit date:2018/12/19
Adam17  Cell Proliferation And Motility  Her Receptor And ligAnds  Inhibitory Antibody  
IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities Journal article
Cancer Letters, 2013,Volume: 340,Issue: 1,Page: 88
Authors:  Li Y.-B.;  Wang Z.-Q.;  Yan X.;  Chen M.-W.;  Bao J.-L.;  Wu G.-S.;  Ge Z.-M.;  Zhou D.-M.;  Wang Y.-T.;  Li R.-T.
Favorite  |  View/Download:3/0  |  Submit date:2018/10/31
Angiogenesis  Breast Cancer  Egfr  Irreversible Tki